Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Outlook 2024

Annual Industry Ranking And Forecast

VIEW NOW

Featured Stories


A Good Choice To Have: Scrip’s Interview With Viking CEO Brian Lian

Still a clinical-stage company, Viking is studying promising candidates for both obesity and MASH in Phase II, but may need to prioritize one while partnering the other.

Exec Chats Business Strategies Companies

Pharma Firms Welcome 'Pragmatic' EU Reforms But Concerns Persist

The European parliament has voted for legislation it says will lead to fairer, more accessible healthcare. The continent's drugmakers are still not wholly convinced.

EU Legislative Reform Market Access Innovation

Venture Capital Fundraising Rebounds In Q1 As Mega-Rounds Dominate

Biopharma firms raised $6bn in the first quarter of 2024, the most of any quarter since Q2 2022. But without an increase in the number of companies raising funds, the rebound remains uneven.

Financing StartUps and SMEs Evaluate Data

Asia Spotlight

Astellas CStO Pearson: We’re Not Short Of Opportunities To Compensate For LOEs

Astellas’ chief strategy officer, Adam Pearson, talks to Scrip about the company’s launch execution thrust for key therapies ahead of the loss of exclusivity for Xtandi and also deal-making appetite and choices, including the Iveric Bio buyout and walking away from the collaboration with Cartesian Therapeutics.


Commercial Business Strategies

More coverage from Scrip's team in Asia

Scrip Podcast

Insights and perspectives on commercial, R&D, deal-making and business strategy developments.

MORE PODCASTS

 

Scrip Originals

Pipeline Watch: Six Approvals And 15 Phase III Updates

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA

Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet

Deal Watch Business Strategies

Executives On The Move: Three New CMOs And CFOs Among This Week's Changes

Recent moves in the industry include C-suite shuffles at PureTech Health and Traws Pharma, plus Xencor gets a new chief financial officer.

Executive Changes Leadership

PureTech Hopes For A Second Lightning Strike

Emerging Company Profile: Seaport Therapeutics believes its technology can alter old drugs to remove their flaws. Just how closely can it follow the example set by Karuna?

Emerging Company Profile Commercial
Interviews

Mural Oncology Primed For IL-2 Readouts Next Year

The company, which Alkermes spun out last year, is now positioned as a pure-play oncology specialist with a focus on cytokines.

ImmunoOncology Cancer

PureTech Hopes For A Second Lightning Strike

Emerging Company Profile: Seaport Therapeutics believes its technology can alter old drugs to remove their flaws. Just how closely can it follow the example set by Karuna?

Emerging Company Profile Commercial

Essential Emerges As A Drug Developer With Renaissance Buy

The acquisition of Renaissance and its promising Phase III-ready asset for neuroblastoma could be the first of a number of deals in the near future, Essential CEO Emma Johnson tells Scrip.

M & A Cancer

AstraZeneca Looks To Many Modalities In Cancer

Mohit Manrao, head of AstraZeneca’s US oncology business unit, explained the company’s diverse approach in an interview, including investments in ADCs, cell therapy and radiopharmaceuticals.

Cancer Business Strategies
See All
Graphics

The Shifting Sands Of Biopharma R&D

A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.

Companies Clinical Trials

Bangers In MASH: How Rezdiffra's Rivals Stack Up

A look at the depth of clinical responses seen with various MASH therapies suggests that Madrigal could eventually face serious competition.

Clinical Trials Liver & Hepatic

A Visual Trip Through The Psychedelic Pipeline

An infographic looking at the status and origins of 39 psychedelic drug development programs being pursued by 26 sponsors. 

Clinical Trials Research & Development

Weighty Matters: The Obesity Market Now… And In Years To Come

INFOGRAPHIC: This overview of the obesity market shows the biggest money-spinners in terms of products and mechanisms, the biggest investors and dealmakers – and looks at how some of the notable current and potential future therapies stack up in the clinic.

Clinical Trials Commercial
See All
Recent Stories

Mural Oncology Primed For IL-2 Readouts Next Year

The company, which Alkermes spun out last year, is now positioned as a pure-play oncology specialist with a focus on cytokines.

ImmunoOncology Cancer

Pipeline Watch: Six Approvals And 15 Phase III Updates

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Pharma On The Hunt For Oncology Partners Across Modalities

The Inaugural AACR Oncology Industry Partnering Event gave pharma firms an opportunity to tell potential cancer drug collaborators what they need from external sources.

Deals Cancer

Novartis Expands In Protein Degradation, Complements Radioligand Platform With Arvinas Deal

Deal Snapshot: The company told Scrip that part of why it licensed Arvinas’s ARV-766 and took over AR-V7 was to complement its radioligand therapy platform in prostate cancer.

Deals Cancer

Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA

Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet

Deal Watch Business Strategies

Sector Stalwart Appalled At Lack Of UK Investor Interest In Biotech

Ali Mortazavi, CEO of e-therapeutics, says the RNAi specialist is delisting from AIM and describes the UK markets as “completely broken and closed” to biotech firms.

Financing Business Strategies

Vertex’s $5bn Alpine Buyout Builds Autoimmune Disease Presence

The company hopes for a “Humira-like” blockbuster with povetacicept, the object of the sector’s biggest M&A deal so far this year.

M & A Commercial

Executives On The Move: Three New CMOs And CFOs Among This Week's Changes

Recent moves in the industry include C-suite shuffles at PureTech Health and Traws Pharma, plus Xencor gets a new chief financial officer.

Executive Changes Leadership

AI Healthcare, Medical Devices Shine In Korea Q1 Financings

After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.

South Korea Artificial Intelligence

Odd Coupling: J&J, RallyBio Collaborate As Only Firms Focused On FNAIT

While not co-developing each other’s drugs, J&J and financially troubled RallyBio are working on complementary approaches to the rare disease fetal and neonatal alloimmune thrombocytopenia.

Rare Diseases Business Strategies

TORL Looks To Break Ground In Growing Field Of Claudin-Targeting Drugs

The company announced a series B-2 financing of $158m that it plans to use for pivotal Phase II development of TORL-1-23, which it called a first-in-class agent.

Financing Business Strategies

Novartis Flies The Flag For US Despite More Job Cuts

It is still “a priority country,” the Switzerland-based giant tells Scrip, as around 240 jobs face the axe at Novartis’s development organizational unit across the Atlantic.

Restructuring Business Strategies
UsernamePublicRestriction

Register